GC Genome

GC Genome FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of GC Genome (340450.KQ) as of Oct 19, 2026 is 23.31 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 3.00 % — a change of 676.77% (higher).

FCF Conversion

23.31 %

YoY

676.77%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of GC Genome is 2025 23.31 % . FCF Conversion Rate (FCF/EBITDA) of GC Genome was 2024 3.00 % . It decreases by 676.77% higher compared to the previous year.

The GC Genome FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
150.94 KRW
Jan 1, 2023
748.00 KRW
Jan 1, 2024
3.00 KRW
Jan 1, 2025
23.31 KRW
The GC Genome FCF Conversion history
YEARFCF ConversionYoY
23.31 %+676.77%
3.00 %-99.60%
748.00 %+395.56%
150.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Genome Stock analysis

What does GC Genome do? GC Genome Corp is a biotechnology company based in Yongin, South Korea, operating within the healthcare sector. The company specializes in clinical genome analysis, focusing on genetic testing services for various medical applications. GC Genome Corp provides prenatal and newborn screening, cancer patient precision diagnosis, and genetic testing for rare diseases. It also offers health checkup test services. The company has 125 full-time employees and completed its initial public offering (IPO) on June 11, 2025. Its headquarters are located in Yongin, Gyeonggi-Do. The company's website is https://www.gcgenome.com/. GC Genome Corp is engaged in the development and delivery of genetic testing solutions tailored to specific healthcare needs, emphasizing precision diagnostics in clinical settings. The firm's services are designed to support medical professionals in making informed decisions regarding patient care through advanced genomic analysis. The company operates in a specialized segment of the biotechnology industry, targeting both clinical and preventive healthcare markets. GC Genome Corp's business model centers on providing accurate and reliable genetic testing services to healthcare providers and patients seeking personalized medical insights. The company's IPO date marks its transition to a publicly traded entity, reflecting its growth and market positioning within the healthcare technology sector. GC Genome is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Genome stock

FCF Conversion Rate (FCF/EBITDA) of GC Genome is 23.31 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of GC Genome changed from 3.00 % to 23.31 %, representing a 676.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) GC Genome since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s GC Genome with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — GC Genome

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — GC Genome